89Zr-DFO-scFv-PEG-Cy5-C 'dot

N/A

Report date: 2025/11/14 17:20:19

Base Information

Drug Name89Zr-DFO-scFv-PEG-Cy5-C 'dot

Drug Alias NameN/A

ClassificationRadiation-emitting products > Nuclides > Zirconium > 89ZrRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionAnti-HER2

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesMedimmune Llc

China Registration ClassN/A

Develop Information

Active CompaniesMedimmune Llc

Inactive CompaniesN/A

Active IndicationsBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A